NCT03616223: A trial that was reported late by Frequency Therapeutics
This trial has reported, although it was 258 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03616223 |
|---|---|
| Title | A Phase 1/2 Randomized, Double-blind, Placebo-controlled Single Dose Study at Two Dose Levels of FX-322 Administered by Intratympanic Injection in Adults With Stable Sensorineural Hearing Loss |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 3, 2018 |
| Completion date | Dec. 18, 2018 |
| Required reporting date | Dec. 18, 2021, midnight |
| Actual reporting date | Sept. 2, 2022 |
| Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
| Days late | 258 |